Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid;Osteonecrosis del maxilar en pacientes con mieloma múltiple durante y después del tratamiento con ácido zoledrónico

Medicina Clinica

Volumn 127, Issue 15, 2006, Pages 576-579

  Calvo Villas, José Manuel ^a   Tapia Torres, María ^b   Govantes Rodríguez, José ^b   Carreter De Granda, Elena ^a   Sicilia Guillén, Francisco ^a  

^a HOSPITAL GENERAL DE LANZAROTE   (Spain)

^b Hospital General de La Palma   (Spain)

Author keywords

Multiple myeloma; Osteonecrosis of the jaw; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; CONTROLLED STUDY; DENTAL SURGERY; DISEASE PREDISPOSITION; HUMAN; JAW; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; ORAL SURGERY; PHYSICAL EXAMINATION;

EID: 33751049624     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(06)72338-7     Document Type: Article

References (20)

1. UK Myeloma Forum, Nordic Myeloma Study Group and British Committee for Standards in Hematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2005;132:410-51.
2. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-36.
3. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996; 334:488-93.
4. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs. 2003;63:417-37.
5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
6. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21:4253-4.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
8. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417-8.
9. Bagan JV, Murillo J, Jiménez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.
10. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
11. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc. 2005;136:1675-81.
12. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005;128:738.
13. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma: clinical features and risk factors. J Clin Oncol. 2006;24:945-52.
14. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-7.
15. United States Food and Drug Administration: Medwatah 2004 safety alert. Zometa (zoledronic acid) injection. Disponible en: http://www.fda.gov/medwatch/ SAFETY/2004/ZometaHCP.pdf
16. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83-93.
17. Santini D, Vincenzi B, Dicuonzo G, Awisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893-7.
18. Expert Panel recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaws: June 2004. Professional education material. East Hanover: Novartis; 2004.
19. Berenson JR. Biphosphonates overview. Disponible en: http:// multiplemyeloma.org/treatments/3.06.html
20. Package Insert Revisions re: Osteonecrosis of the jaw: Zometa (zoledronic acid) injection and Aredia (pamidronate disodium) injection. Oncologic Drugs Advisory Committee Meeting; 2005, March 4. Disponible en: http://www.fda.gov